Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

VOLT CE Mark Study

NCT: NCT06106594 · ACTIVE_NOT_RECRUITING

NCT IDNCT06106594
StatusACTIVE_NOT_RECRUITING
Start Date2023-10-24
Completion2026-12

Brief Summary

This clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™ X EP System EnSite™ Pulsed Field Ablation Module (for simplicity of reference this device collection will hereafter be referred to as the Volt™ PFA system) for the treatment of symptomatic, recurrent, drug-refractory paroxysmal and persistent atrial fibrillation.

Frequently Asked Questions

What is VOLT CE Mark Study?

VOLT CE Mark Study is a clinical trial registered under NCT06106594. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06106594?

The current status of NCT06106594 (VOLT CE Mark Study) is: ACTIVE_NOT_RECRUITING.

When did VOLT CE Mark Study start?

VOLT CE Mark Study started on 2023-10-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑